Shopping Cart
- Remove All
Your shopping cart is currently empty
UNC569
UNC569 (UNC 569) is a selective inhibitor of URAT1, a transporter in the kidney that regulates uric acid excretion from the body. It is also a selective uric acid re-absorption inhibitor. UNC569 could normalize the amount of uric acid excreted by gout patients previously classified as under-excretors.
Catalog No. T21302Cas No. 1350547-65-7
Select Batch
Purity:98.91%
Contact us for more batch information
UNC569
Catalog No. T21302Alias UNC 569Cas No. 1350547-65-7
UNC569 (UNC 569) is a selective inhibitor of URAT1, a transporter in the kidney that regulates uric acid excretion from the body. It is also a selective uric acid re-absorption inhibitor. UNC569 could normalize the amount of uric acid excreted by gout patients previously classified as under-excretors.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $38 | In Stock | |
| 2 mg | $54 | In Stock | |
| 5 mg | $89 | In Stock | |
| 10 mg | $147 | In Stock | |
| 25 mg | $328 | In Stock | |
| 50 mg | $538 | In Stock | |
| 100 mg | $768 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $97 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "UNC569"
Gilteritinib
Cited
ASP2215
T44091254053-43-4
Gilteritinib (ASP2215) is a potent inhibitor of FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectively). In preclinical studies, gilteritinib demonstrated strong antileukemic and antitumor effects. Gilteritinib is currently in several Phase 3 clinical trials for acute myeloid leukemia.
- $34
Size
QTY
CitedCabozantinib S-malate
Cabozantinib, XL184, Cabozantinib Malate
T17971140909-48-3
Cabozantinib S-malate (XL184) is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity.
- $40
Size
QTY
UNC2025
mrx-6313, UNC-2025, UNC 2025
T70071429881-91-3
UNC2025 (mrx-6313)(IC50 of 0.74 nM and 0.8 nM) is a potent and orally bioavailable dual MER/FLT3 inhibitor. UNC-2025 is about 20-fold selectivity higher than Axl and Tyro3.
- $33
Size
QTY
Bemcentinib Cited
R428, BGB324
T62691037624-75-1
Bemcentinib (R428) is a selective inhibitor of Axl (IC50: 14 nM) and has been investigated for the treatment of NSCLC.
- $34
Size
QTY
CitedSitravatinib Cited
MG516, MGCD516
T43491123837-84-2
Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
- $47
Size
QTY
CitedNCT-503 Cited
NCT 503
T42131916571-90-8
NCT-503 is a phosphoglycerate dehydrogenase (PHGDH) inhibitor (IC50=2.5 µM) with no activity against other dehydrogenases. NCT-503 has antitumor activity and inhibits the growth of PHGDH-dependent tumors.
- $35
Size
QTY
CitedCabozantinib Cited
XL184, BMS-907351
T2586849217-68-1
Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM). Cabozantinib exhibits both antitumor and antiangiogenic activity.
- $39
Size
QTY
CitedSGI-7079
T69821239875-86-5
SGI-7079 is a new selective Axl inhibitor. SGI-7079 can be a dose-dependent manner inhibited growth of tumors. It is also a potential therapeutic target for EGFR inhibitor resistance.
- $35
Size
QTY
Dubermatinib
TP0903
T20051341200-45-0
Dubermatinib (TP0903) is a potent and selective Axl kinase inhibitor.
- $30
Size
QTY
AXL-IN-13
T733002376928-82-2In house
AXL-IN-13 is a potent and orally active AXL inhibitor with an IC50 of 1.6 nM and a Kd of 0.26 nM. It exhibits anticancer activity, reverses TGF-β1-induced epithelial-mesenchymal transition (EMT), and inhibits cancer cell migration and invasion.
- $79
Size
QTY
G-749
G749, Denfivontinib
T26201457983-28-6
G-749, a new-type FLT3 inhibitor, exhibits effective and sustained inhibition of the FLT3 wild type and mutants.
- $40
Size
QTY
BMS 777607
BMS777607, BMS-777607, BMS 817378
T26991025720-94-8
BMS 777607 (BMS 817378) is a Met-related inhibitor targeting c-Met, Axl, Ron, and Tyro3 with IC50 values of 3.9 nM, 1.1 nM, 1.8 nM, and 4.3 nM, respectively. BMS-777607 has been investigated in basic science research for malignant solid tumors.
- $32
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
| Description | UNC569 (UNC 569) is a selective inhibitor of URAT1, a transporter in the kidney that regulates uric acid excretion from the body. It is also a selective uric acid re-absorption inhibitor. UNC569 could normalize the amount of uric acid excreted by gout patients previously classified as under-excretors. |
| Targets&IC50 | Mer:2.9 nM(IC50), Mer:4.3 nM(Ki), Axl:37 nM(IC50) |
| Alias | UNC 569 |
| Molecular Weight | 396.5 |
| Formula | C22H29FN6 |
| Cas No. | 1350547-65-7 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO: 6.25 mg/mL, Sonication is recommended. H2O: Insoluble |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy UNC569 | purchase UNC569 | UNC569 cost | order UNC569 | UNC569 chemical structure | UNC569 formula | UNC569 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.